Possibilities Beyond Limits

Lotte Biologics is a global CDMO specializing in mammalian cell-based production and Antibody-Drug Conjugates (ADC), leveraging over 20 years of manufacturing experience. The company operates a dual-site strategy with a unified quality system across its Syracuse, New York, and Songdo, South Korea campuses. The Syracuse facility is a premier U.S. site for ADC conjugation, offering both clinical and commercial drug substance manufacturing with a 98% batch success rate and zero FDA observations in 2024. Expansion is underway at the Songdo Bio Campus, which is scheduled for GMP readiness by Q4 2027 to provide large-scale 15KL bioreactor capacity.

To accelerate client timelines, the company offers streamlined processes that can move a project from cell line development to IND in just 10 months, or 12 months for complex ADC parallel development. Their technical offerings include the SoluFlex Link™ platform for improved ADC solubility and the TiterFlex Quad™ system for high-titer production. Operations are supported by a 24/7 digital customer service platform that provides real-time batch tracking and transparent data access. As part of the Lotte Group, the company is also committed to ESG management, ensuring that its global health impact is delivered through sustainable and reliable manufacturing practices.